National Cancer Institute to Test Serenex Compound
The compound has shown “exceptional efficacy” in preclinical studies, according to Serenex Chief Executive Officer Richard Kent. The work with the NCI could lead to the launch of clinical trials in patients with lung cancer, Kent added.
This entry was posted on Friday, January 25th, 2008 at 11:24 am and is filed under Research. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.